Endocyte Announces Presentations at American Association for Cancer Research (AACR) Annual Meeting 2018
March 15 2018 - 4:01PM
Endocyte, Inc. (Nasdaq:ECYT), a biopharmaceutical company
developing targeted therapeutics for personalized cancer treatment,
today announced that four posters will be presented by Endocyte
scientists at the American Association for Cancer Research (AACR)
Annual Meeting 2018 to be held in Chicago, IL, April 14 - 18, 2018.
The company will present two posters and a late-breaking
abstract relating to Endocyte’s chimeric antigen receptor T-cell
(CAR T) adaptor molecule (CAM) platform, along with a poster on
PSMA-617.
Presentations are as follows:
|
|
Abstract #: |
757 |
Title: |
Novel
warheads for targeted therapies of cancer: The concept and design
of oxime-ether-based pro-PBDs |
When: |
Sunday,
April 15, 1 p.m. – 5 p.m. CDT |
Session Title: |
Antibody-Drug Conjugates: Agents and Technology |
Location: |
Hall A,
Poster Section 35, Poster Board 24 |
|
|
Abstract #: |
852 |
Title: |
Specificity of PSMA-617 radiotherapy for prostate cancer |
When: |
Sunday,
April 15, 1 p.m. – 5 p.m. CDT |
Session Title: |
Modulators of Ionizing Radiation and Other Radiotherapeutics |
Location: |
Hall A,
Poster Section 39, Poster Board 15 |
|
|
Abstract #: |
LB-109 |
Title: |
Adaptor
controlled CAR-T cell immunotherapy for treatment of folate
receptor-alpha/beta positive solid and liquid tumors |
When: |
Monday,
April 16, 8 a.m. – 12:00 p.m. CDT |
Session Title: |
Late-Breaking Research: Immunology 1 |
Location: |
Hall A,
Poster Section 45, Poster Board 6 |
|
|
Abstract #: |
2546 |
Title: |
Regulation of CAR-T cell therapy in real time using bispecific
small molecule adaptors and monospecific competitors |
When: |
Monday,
April 16, 1 p.m. – 5 p.m. CDT |
Session Title: |
Adoptive
Cell Therapy 2 |
Location: |
Hall A,
Poster Section 24, Poster Board 4 |
|
|
Website InformationEndocyte
routinely posts important information for investors on its website,
www.endocyte.com, in the “Investors & News” section. Endocyte
uses this website as a means of disclosing material information in
compliance with its disclosure obligations under Regulation
FD. Accordingly, investors should monitor the “Investors &
News” section of Endocyte’s website, in addition to following its
press releases, SEC filings, public conference calls, presentations
and webcasts. The information contained on, or that may be
accessed through, Endocyte’s website is not incorporated by
reference into, and is not a part of, this document.
About Endocyte
Endocyte is a biopharmaceutical company and leader in developing
targeted therapies for the personalized treatment of cancer. The
company's drug conjugation technology targets therapeutics and
companion imaging agents specifically to the site of diseased
cells. Endocyte's lead program is a prostate specific membrane
antigen (PSMA)-targeted radioligand therapy, 177Lu-PSMA-617,
entering phase 3 for metastatic castration resistant prostate
cancer (mCRPC). Endocyte is also advancing its adaptor-controlled
CAR T-cell therapy into the clinic in 2018, where it will be
studied in osteosarcoma. For additional information, please visit
Endocyte's website at www.endocyte.com.
Forward Looking Statements
Certain of the statements made in this press release are forward
looking, such as those, among others, relating to the company's
future development plans including those relating to the completion
of pre-clinical development in preparation for possible future
clinical trials, the anticipated initiation of a registration
trial, and preparation for potential commercialization. Actual
results or developments may differ materially from those projected
or implied in these forward-looking statements. Factors that may
cause such a difference include risks that the company or
independent investigators may experience delays in the initiation
or completion of clinical trials (whether caused by competition,
adverse events, patient enrollment rates, shortage of clinical
trial materials, regulatory issues or other factors); risks that
data from prior clinical trials may not be indicative of subsequent
clinical trial results; risks related to the safety and efficacy of
the company’s product candidates; risks that early stage
pre-clinical data may not be indicative of subsequent data when
expanded to additional pre-clinical models or to subsequent
clinical data; risks that evolving competitive activity and
intellectual property landscape may impair the company's ability to
capture value for the technology; risks that expectations and
estimates turn out to be incorrect, including estimates of the
potential markets for the company’s product candidates, estimates
of the capacity of manufacturing and other facilities required to
support its product candidates, projected cash needs, and expected
future revenues, operations, expenditures and cash position. More
information about the risks and uncertainties faced by Endocyte,
Inc. is contained in the company’s periodic reports filed with the
Securities and Exchange Commission. Endocyte, Inc. disclaims any
intention or obligation to update or revise any forward-looking
statements, whether as a result of new information, future events
or otherwise.
Investor Contact:
Stephanie Ascher, Stern Investor Relations, Inc., (212)
362-1200, stephanie@sternir.com
Endocyte, Inc. (delisted) (NASDAQ:ECYT)
Historical Stock Chart
From Mar 2024 to Apr 2024
Endocyte, Inc. (delisted) (NASDAQ:ECYT)
Historical Stock Chart
From Apr 2023 to Apr 2024